National Cancer Institute (NCI)

239 results found.

Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, or Clinical Trial using ipilimumab; recombinant interferon alfa-2b; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.
ipilimumab; recombinant interferon alfa-2b; quality-of-life assessment

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using alisertib; romidepsin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas.
alisertib; romidepsin; laboratory biomarker analysis

Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicul Clinical Trial using ibrutinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma.
ibrutinib; laboratory biomarker analysis

Disseminated Neuroblastoma, Localized Unresectable Neuroblastoma, Clinical Trial using vorinostat; isotretinoin; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 30 years.
- Phase I Study of Vorinostat in Combination With 13-Cis-Retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma.
vorinostat; isotretinoin; pharmacological study; laboratory biomarker analysis

Leukemia, or Lymphoma Clinical Trial using valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL.
valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma Clinical Trial using trebananib; placebo; bevacizumab; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma.
trebananib; placebo; bevacizumab; pharmacological study; laboratory biomarker analysis

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS.
cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial C Clinical Trial using IDO1 inhibitor INCB024360; therapeutic conventional surgery; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 19 years or older.
- A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.
IDO1 inhibitor INCB024360; therapeutic conventional surgery; laboratory biomarker analysis

Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using bortezomib; dexamethasone

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy.
bortezomib; dexamethasone

Kidney Cancer Clinical Trial using aldesleukin; bevacizumab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Study of Bevacizumab and Aldesleukin in Patients With Metastatic Renal Cell Carcinoma (RCC): A Cytokine Working Group (CWG) Study.
aldesleukin; bevacizumab

Childhood Mixed Glioma, Untreated Childhood Anaplastic Astrocytom Clinical Trial using veliparib; temozolomide; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- A Phase I/II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG).
veliparib; temozolomide; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy; pharmacological study; laboratory biomarker analysis

Recurrent Small Cell Lung Cancer Clinical Trial using linsitinib; topotecan hydrochloride; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC).
linsitinib; topotecan hydrochloride; laboratory biomarker analysis; pharmacological study

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using daunorubicin hydrochloride; cytarabine; decitabine; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML).
daunorubicin hydrochloride; cytarabine; decitabine; laboratory biomarker analysis; pharmacological study

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; bortezomib; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma.
alisertib; bortezomib; rituximab; laboratory biomarker analysis

Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Desmo Clinical Trial using vismodegib; gamma-secretase/Notch signalling pathway inhibitor RO4929097; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas.
vismodegib; gamma-secretase/Notch signalling pathway inhibitor RO4929097; laboratory biomarker analysis; pharmacological study

Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Diffuse Clinical Trial using doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma.
doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage Clinical Trial using ofatumumab; bendamustine hydrochloride; bortezomib; laboratory biomarker analysis; positron emission tomography with radiolabeled targeting agents; fludeoxyglucose F 18

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma.
ofatumumab; bendamustine hydrochloride; bortezomib; laboratory biomarker analysis; positron emission tomography with radiolabeled targeting agents; fludeoxyglucose F 18

Recurrent Adult Hodgkin Lymphoma, or Recurrent/Refractory Childho Clinical Trial using brentuximab vedotin; gemcitabine hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 13 Months to 30 years.
- A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND# 117117) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma.
brentuximab vedotin; gemcitabine hydrochloride; laboratory biomarker analysis

Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontigu Clinical Trial using lenalidomide; rituximab; cyclophosphamide; doxorubicin hydrochloride; vincristine sulfate; prednisone; laboratory biomarker analysis; positron emission tomography

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
lenalidomide; rituximab; cyclophosphamide; doxorubicin hydrochloride; vincristine sulfate; prednisone; laboratory biomarker analysis; positron emission tomography

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocyti Clinical Trial using ibrutinib; rituximab; bendamustine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 65 years or older.
- A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (ò 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL).
ibrutinib; rituximab; bendamustine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Hepatic Complications, Renal Failure, or Unspecified Adult Solid Clinical Trial using dabrafenib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction.
dabrafenib; pharmacological study; laboratory biomarker analysis

B-cell Adult Acute Lymphoblastic Leukemia, Philadelphia Chromosom Clinical Trial using cytarabine; daunorubicin hydrochloride; vincristine sulfate; dexamethasone; methotrexate; pegaspargase; cyclophosphamide; mercaptopurine tablet; blinatumomab; etoposide; prednisone; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 35 years to 70 years.
- A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.
cytarabine; daunorubicin hydrochloride; vincristine sulfate; dexamethasone; methotrexate; pegaspargase; cyclophosphamide; mercaptopurine tablet; blinatumomab; etoposide; prednisone; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

Lung Cancer Clinical Trial using bexarotene; capecitabine; carboplatin; cisplatin; docetaxel; tretinoin

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Bexarotene (Targretin) Capsules With Tretinoin and Chemotherapy in Patients With Advanced Non-small-cell Lung Cancer.
bexarotene; capecitabine; carboplatin; cisplatin; docetaxel; tretinoin

Non-melanomatous Skin Cancer Clinical Trial using aminolevulinic acid hydrochloride

National Cancer Institute (NCI) - Recruiting 30 years or older.
- Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma.
aminolevulinic acid hydrochloride

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using wild-type reovirus; paclitaxel

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II EVALUATION OF WEEKLY PACLITAXEL (NSC# 673089) VERSUS WEEKLY PACLITAXEL WITH ONCOLYTIC REOVIRUS (REOLYSIN NSC # 729968, BB-IND #13370) IN THE TREATMENT OF RECURRENT OR PERSISTENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
wild-type reovirus; paclitaxel

Recurrent Squamous Cell Carcinoma of the Nasopharynx, or Stage IV Clinical Trial using Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma.
Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

HER2-positive Breast Cancer, Inflammatory Breast Cancer, Male Bre Clinical Trial using entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed.
entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using romidepsin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
romidepsin; pharmacological study

Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Clinical Trial using ipilimumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies.
ipilimumab; laboratory biomarker analysis

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; idarubicin; vorinostat; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 60 years.
- A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA+V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML).
cytarabine; daunorubicin hydrochloride; idarubicin; vorinostat; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

Colorectal Cancer, or Healthy, no Evidence of Disease Clinical Trial using linaclotide acetate; placebo; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- Phase I, Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Colorectal Bioactivity in Healthy Volunteers.
linaclotide acetate; placebo; pharmacological study; laboratory biomarker analysis

Prostate Cancer Clinical Trial using antiandrogen therapy; releasing hormone agonist therapy; DNA analysis; RNA analysis; comparative genomic hybridization; gene expression analysis; laboratory biomarker analysis; diffusion-weighted magnetic resonance imaging; magnetic resonance spectroscopic imaging

National Cancer Institute (NCI) - Recruiting N/A or older.
- A Study of Changes in the Prostate Following Androgen Deprivation to Investigate Therapy Response and Resistance in Clinical Prostate Cancer.
antiandrogen therapy; releasing hormone agonist therapy; DNA analysis; RNA analysis; comparative genomic hybridization; gene expression analysis; laboratory biomarker analysis; diffusion-weighted magnetic resonance imaging; magnetic resonance spectroscopic imaging

Melanoma (Skin) Clinical Trial using cisplatin; sorafenib tosylate; tamoxifen citrate; adjuvant therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Pilot Trial of Sorafenib, Tamoxifen and Cisplatin as Adjuvant Therapy for Patients With Stage III Malignant Melanoma.
cisplatin; sorafenib tosylate; tamoxifen citrate; adjuvant therapy

Melanoma (Skin) Clinical Trial using bevacizumab; oxaliplatin; sorafenib tosylate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of Nexavar, Avastin and Eloxatin in Patients With Metastatic Malignant Melanoma.
bevacizumab; oxaliplatin; sorafenib tosylate

Bladder Cancer Clinical Trial using quality-of-life assessment; questionnaire administration

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [QOL].
quality-of-life assessment; questionnaire administration

Bladder Cancer Clinical Trial using selenium; vitamin E; chemoprevention

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT].
selenium; vitamin E; chemoprevention

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkins Lymphoma.
veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

Kidney Cancer Clinical Trial using sunitinib malate; gene expression analysis; reverse transcriptase-polymerase chain reaction; western blotting; immunohistochemistry staining method; laboratory biomarker analysis; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma.
sunitinib malate; gene expression analysis; reverse transcriptase-polymerase chain reaction; western blotting; immunohistochemistry staining method; laboratory biomarker analysis; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

Recurrent Melanoma, Recurrent Thyroid Cancer, Thyroid Gland Medul Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 18 years.
- A Phase 1 Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

Lymphoma Clinical Trial using autologous immunoglobulin idiotype-KLH conjugate vaccine; rituximab; sargramostim

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Maintenance Rituximab Plus FavIdr and GM-CSF Immunotherapy in Patients With Treatment-Naive Indolent B-Cell Lymphoma.
autologous immunoglobulin idiotype-KLH conjugate vaccine; rituximab; sargramostim

Bladder Cancer Clinical Trial using medical chart review; questionnaire administration; study of socioeconomic and demographic variables

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [COHORT].
medical chart review; questionnaire administration; study of socioeconomic and demographic variables

Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Clinical Trial using pazopanib hydrochloride; placebo; quality-of-life assessment; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors.
pazopanib hydrochloride; placebo; quality-of-life assessment; laboratory biomarker analysis

Stage II Childhood Anaplastic Large Cell Lymphoma, Stage III Chil Clinical Trial using brentuximab vedotin; crizotinib; dexamethasone; ifosfamide; methotrexate; cytarabine; etoposide; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) IND # 117117.
brentuximab vedotin; crizotinib; dexamethasone; ifosfamide; methotrexate; cytarabine; etoposide; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis

Metastatic Cancer Clinical Trial using conventional surgery; intraoperative radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Study Utilizing the Zeiss INTRABEAM System for the Treatment of a Resected Solitary Brain Metastasis.
conventional surgery; intraoperative radiation therapy

Brain and Central Nervous System Tumors Clinical Trial using carboplatin; tamoxifen citrate; temozolomide; adjuvant therapy; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas.
carboplatin; tamoxifen citrate; temozolomide; adjuvant therapy; radiation therapy

Kidney Cancer Clinical Trial using motexafin gadolinium; sunitinib malate; comparative genomic hybridization; gene expression analysis; mutation analysis; polymorphism analysis; immunohistochemistry staining method; iodine I-124 girentuximab; laboratory biomarker analysis; pharmacological study; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Histopathologic and Imaging Study of Renal Cell Carcinoma Vasculature in the Setting of Sunitinib Therapy Prior to Cytoreductive Nephrectomy.
motexafin gadolinium; sunitinib malate; comparative genomic hybridization; gene expression analysis; mutation analysis; polymorphism analysis; immunohistochemistry staining method; iodine I-124 girentuximab; laboratory biomarker analysis; pharmacological study; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Ca Clinical Trial using systemic chemotherapy; tamoxifen citrate; anastrozole; exemestane; letrozole

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE III, RANDOMIZED CLINICAL TRIAL OF STANDARD ADJUVANT ENDOCRINE THERAPY +/-CHEMOTHERAPY IN PATIENTS WITH 1-3 POSITIVE NODES, HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE BREAST CANCER WITH RECURRENCE SCORE (RS) OF 25 OR LESS. RXPONDER: A CLINICAL TRIAL RX FOR POSITIVE NODE, ENDOCRINE RESPONSIVE BREAST CANCER.
systemic chemotherapy; tamoxifen citrate; anastrozole; exemestane; letrozole

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Clinical Trial using filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 16 years to 65 years.
- A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies.
filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, or S Clinical Trial using wild-type reovirus; carboplatin; paclitaxel

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysinr) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer.
wild-type reovirus; carboplatin; paclitaxel

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Na‹ve Patients With Recurrent Glioblastoma Multiforme.
anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.
alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Ca Clinical Trial using docetaxel; carboplatin; trastuzumab; pertuzumab; goserelin acetate; therapeutic conventional surgery; whole breast irradiation; quality-of-life assessment; laboratory biomarker analysis; aromatase inhibition therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation.
docetaxel; carboplatin; trastuzumab; pertuzumab; goserelin acetate; therapeutic conventional surgery; whole breast irradiation; quality-of-life assessment; laboratory biomarker analysis; aromatase inhibition therapy

Brain and Central Nervous System Tumors Clinical Trial using antineoplaston A10; antineoplaston AS2-1

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma.
antineoplaston A10; antineoplaston AS2-1

Colorectal Cancer Clinical Trial using loss of heterozygosity analysis; microsatellite instability analysis; mutation analysis; counseling intervention

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Outcomes in Education and Counseling for HNPCC Testing.
loss of heterozygosity analysis; microsatellite instability analysis; mutation analysis; counseling intervention

Brain and Central Nervous System Tumors Clinical Trial using cisplatin; cyclophosphamide; etoposide; lomustine; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 3 years to 30 years.
- Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma).
cisplatin; cyclophosphamide; etoposide; lomustine; vincristine sulfate

Lymphoma Clinical Trial using alemtuzumab; cyclophosphamide; fludarabine phosphate

National Cancer Institute (NCI) - Recruiting 18 years to 70 years.
- A Phase I/II Study Of HLA-Matched Mobilized Peripheral Blood Hematopoetic Stem Cell Transplantation For Advanced Mycosis Fungoides/Sezary Using NonMyeloablative Conditioning With Campath-1H.
alemtuzumab; cyclophosphamide; fludarabine phosphate

Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Sta Clinical Trial using ziv-aflibercept; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study to Determine the Effect of 2 Different Doses AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma.
ziv-aflibercept; laboratory biomarker analysis

Lymphoma Clinical Trial using alemtuzumab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate; flow cytometry; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study.
alemtuzumab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate; flow cytometry; pharmacological study

Leukemia, or Myelodysplastic Syndromes Clinical Trial using anti-thymocyte globulin; peripheral blood lymphocyte therapy; fludarabine phosphate; methylprednisolone; thiotepa; allogeneic hematopoietic stem cell transplantation; in vitro-treated peripheral blood stem cell transplantation; total-body irradiation

National Cancer Institute (NCI) - Recruiting N/A to 50 years.
- Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation From a Haploidentical Donor for Patients With Acute Leukemia and Myelodysplasia.
anti-thymocyte globulin; peripheral blood lymphocyte therapy; fludarabine phosphate; methylprednisolone; thiotepa; allogeneic hematopoietic stem cell transplantation; in vitro-treated peripheral blood stem cell transplantation; total-body irradiation

Colorectal Cancer Clinical Trial using panitumumab; cyclosporine; irinotecan hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)].
panitumumab; cyclosporine; irinotecan hydrochloride

Colorectal Cancer Clinical Trial using cetuximab; irinotecan hydrochloride; conventional surgery; neoadjuvant therapy; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years to 74 years.
- Neoadjuvant Conformal Radiotherapy and Concomitant CPT-11 and EGFR Inhibition With Cetuximab in Patients With Rectal Cancer Phase I Study.
cetuximab; irinotecan hydrochloride; conventional surgery; neoadjuvant therapy; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy

Lung Cancer Clinical Trial using therapeutic thoracoscopy; videothoracoscopy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (ó 2 CM) Peripheral Non-Small Cell Lung Cancer.
therapeutic thoracoscopy; videothoracoscopy

Esophageal Cancer, or Precancerous Condition Clinical Trial using erlotinib hydrochloride; laboratory biomarker analysis; biopsy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Chemoprevention Trial Using Erlotinib in Barrett's Esophagus With High-Grade Dysplasia.
erlotinib hydrochloride; laboratory biomarker analysis; biopsy

Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using bortezomib; hydroxychloroquine; immunologic technique; laboratory biomarker analysis; mass spectrometry; pharmacological study; biopsy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed/Refractory Myeloma.
bortezomib; hydroxychloroquine; immunologic technique; laboratory biomarker analysis; mass spectrometry; pharmacological study; biopsy

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using docetaxel; cisplatin; carboplatin; fluorouracil; bevacizumab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
docetaxel; cisplatin; carboplatin; fluorouracil; bevacizumab

Prostate Cancer Clinical Trial using docetaxel; sorafenib tosylate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Study of Sorafenib in Combination With Docetaxel in Patients With Androgen-Independent Prostate Cancer.
docetaxel; sorafenib tosylate

Brain and Central Nervous System Tumors Clinical Trial using adjuvant therapy; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years to 70 years.
- Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study.
adjuvant therapy; radiation therapy

Brain and Central Nervous System Tumors Clinical Trial using temozolomide; DNA methylation analysis; laboratory biomarker analysis; adjuvant therapy; quality-of-life assessment; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial..
temozolomide; DNA methylation analysis; laboratory biomarker analysis; adjuvant therapy; quality-of-life assessment; radiation therapy

Colorectal Cancer Clinical Trial using bevacizumab; fluorouracil; irinotecan hydrochloride; leucovorin calcium

National Cancer Institute (NCI) - Recruiting 18 years to 74 years.
- Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28: Prospective, Phase II, Multicenter Study.
bevacizumab; fluorouracil; irinotecan hydrochloride; leucovorin calcium

Breast Cancer Clinical Trial using trastuzumab; parenteral chemotherapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Persephone: Duration of Trastuzumab With Chemotherapy in Women With Early Stage Breast Cancer: Six Months Versus Twelve.
trastuzumab; parenteral chemotherapy

Head and Neck Cancer Clinical Trial using positron emission tomography/computed tomography; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer.
positron emission tomography/computed tomography; therapeutic conventional surgery

Head and Neck Cancer, Infection, or Malnutrition Clinical Trial using therapeutic nutritional supplementation; placebo

National Cancer Institute (NCI) - Recruiting 18 years to 75 years.
- Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract.
therapeutic nutritional supplementation; placebo

Esophageal Cancer Clinical Trial using cisplatin; fluorouracil; radiation therapy

National Cancer Institute (NCI) - Recruiting 20 years to 74 years.
- An Investigational Study of Chemoradiosensitivity Prediction With Genetic Profiling of Esophageal Biopsy for Squamous Cell Carcinoma of the Esophagus.
cisplatin; fluorouracil; radiation therapy

Head and Neck Cancer Clinical Trial using chemotherapy; diagnostic laboratory biomarker analysis; tissue oxygen measurement; blood-oxygen-level-dependent functional magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; magnetic resonance spectroscopic imaging; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Predicting Treatment Response Based on Hypoxia in Head and Neck Cancers Using Non-Invasive Oxygen Sensitive MRI.
chemotherapy; diagnostic laboratory biomarker analysis; tissue oxygen measurement; blood-oxygen-level-dependent functional magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; magnetic resonance spectroscopic imaging; radiation therapy

Lymphoma Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A or older.
- Hodgkin Disease (HD) Banking Study.
biologic sample preservation procedure

Brain and Central Nervous System Tumors Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A to 18 years.
- A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens.
biologic sample preservation procedure

Breast Cancer Clinical Trial using exemestane; sunitinib malate; placebo

National Cancer Institute (NCI) - Recruiting N/A or older.
- Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer..
exemestane; sunitinib malate; placebo

Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Clinical Trial using crizotinib; pharmacogenomic studies; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneou Clinical Trial using O6-benzylguanine; carmustine; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 19 years or older.
- Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma.
O6-benzylguanine; carmustine; laboratory biomarker analysis

Breast Cancer, Cancer Survivor, Fatigue, or Psychosocial Effects Clinical Trial using protein analysis; laboratory biomarker analysis; mass spectrometry; questionnaire administration; assessment of therapy complications; cognitive assessment; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A or older.
- Biological Mechanisms of Fatigue in Breast Cancer Survivors.
protein analysis; laboratory biomarker analysis; mass spectrometry; questionnaire administration; assessment of therapy complications; cognitive assessment; quality-of-life assessment

Adenomatous Polyp Clinical Trial using eflornithine; acetylsalicylic acid; placebo; laboratory biomarker analysis; telephone-based intervention

National Cancer Institute (NCI) - Recruiting 40 years or older.
- Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer.
eflornithine; acetylsalicylic acid; placebo; laboratory biomarker analysis; telephone-based intervention

Prostate Cancer, or Sexual Dysfunction Clinical Trial using laboratory biomarker analysis; questionnaire administration; assessment of therapy complications; high-intensity focused ultrasound ablation; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A or older.
- HIFU Lesion Control in Patients With Non-metastatic Progressive Prostate Cancer.
laboratory biomarker analysis; questionnaire administration; assessment of therapy complications; high-intensity focused ultrasound ablation; quality-of-life assessment

Lung Cancer Clinical Trial using docetaxel; erlotinib hydrochloride; pemetrexed disodium; fluorescence in situ hybridization; mutation analysis; proteomic profiling; immunohistochemistry staining method; laboratory biomarker analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; breath test

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer.
docetaxel; erlotinib hydrochloride; pemetrexed disodium; fluorescence in situ hybridization; mutation analysis; proteomic profiling; immunohistochemistry staining method; laboratory biomarker analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; breath test

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using veliparib; mitomycin C; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair.
veliparib; mitomycin C; laboratory biomarker analysis

Leukemia, or Lymphoma Clinical Trial using anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 18 years to 69 years.
- Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL).
anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

Malignant Mesothelioma Clinical Trial using pemetrexed disodium; clinical observation

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients With Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy.
pemetrexed disodium; clinical observation

Lymphoma Clinical Trial using cyclophosphamide; prednisolone; vinblastine sulfate; watchful waiting; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting N/A to 17 years.
- First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents.
cyclophosphamide; prednisolone; vinblastine sulfate; watchful waiting; therapeutic conventional surgery

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using temozolomide; veliparib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias.
temozolomide; veliparib; pharmacological study; laboratory biomarker analysis

Head and Neck Cancer, Ototoxicity, or Radiation Toxicity Clinical Trial using adjuvant therapy; assessment of therapy complications; quality-of-life assessment; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multicenter Randomized Study of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy in Patients With Parotid Tumors.
adjuvant therapy; assessment of therapy complications; quality-of-life assessment; 3-dimensional conformal radiation therapy; intensity-modulated radiation therapy

Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Clinical Trial using vorinostat; bevacizumab; temozolomide

National Cancer Institute (NCI) - Recruiting 3 years to 21 years.
- A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND# 7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas.
vorinostat; bevacizumab; temozolomide

Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-posit Clinical Trial using veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors.
veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adeno Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Pre Clinical Trial using sorafenib tosylate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 30 years.
- A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma.
sorafenib tosylate; pharmacological study; laboratory biomarker analysis

Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor, o Clinical Trial using linsitinib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 2 Study of OSI-906 in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors.
linsitinib; pharmacological study; laboratory biomarker analysis

Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of Clinical Trial using Akt inhibitor MK2206; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation.
Akt inhibitor MK2206; laboratory biomarker analysis; pharmacological study

Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ Clinical Trial using docosahexaenoic acid; placebo; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.
docosahexaenoic acid; placebo; laboratory biomarker analysis

Recurrent Non-small Cell Lung Cancer, or Stage IV Non-small Cell Clinical Trial using cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy.
cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

Healthy, no Evidence of Disease Clinical Trial using retinoid 9cUAB30; placebo; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Phase I Dose-escalation Study of the Novel Retinoid 9cUAB30.
retinoid 9cUAB30; placebo; laboratory biomarker analysis; pharmacological study

Adenomatous Polyp, Colon Cancer, Stage IIA Colon Cancer, Stage II Clinical Trial using defined green tea catechin extract; placebo; laboratory biomarker analysis; questionnaire administration

National Cancer Institute (NCI) - Recruiting 40 years or older.
- Randomized Phase II Trial of Polyphenon E vs. Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.
defined green tea catechin extract; placebo; laboratory biomarker analysis; questionnaire administration

Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent S Clinical Trial using soy isoflavones; laboratory biomarker analysis; survey administration

National Cancer Institute (NCI) - Recruiting 19 years to 79 years.
- A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma.
soy isoflavones; laboratory biomarker analysis; survey administration

Prostate Cancer Clinical Trial using bicalutamide; goserelin acetate; clinical observation

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III.
bicalutamide; goserelin acetate; clinical observation

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using carboplatin; ifosfamide; hyperthermia treatment

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY.
carboplatin; ifosfamide; hyperthermia treatment

Breast Cancer Clinical Trial using 3-dimensional conformal accelerated partial breast irradiation; brachytherapy; whole breast irradiation

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer.
3-dimensional conformal accelerated partial breast irradiation; brachytherapy; whole breast irradiation

Prostate Cancer Clinical Trial using flutamide; triptorelin; neoadjuvant therapy; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 74 years.
- Multicentre Randomized Trial Assessing the Efficacy of a Short Neoadjuvant and Concomitant Hormone Therapy to an Exclusive Curative Cornformational Radiotherapy of Locolized Prostate Cancer With Intermediate Prognosis.
flutamide; triptorelin; neoadjuvant therapy; radiation therapy

Lymphoma Clinical Trial using rituximab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma.
rituximab

Sarcoma Clinical Trial using dactinomycin; cyclophosphamide; vincristine sulfate; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 17 years.
- Phase II Trial of Short VAC1.2 Therapy for Low-Risk A Group Patients With Rhabdomyosarcoma.
dactinomycin; cyclophosphamide; vincristine sulfate; radiation therapy

Lymphoma Clinical Trial using rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 18 years to 60 years.
- Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study].
rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

Leukemia Clinical Trial using rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT).
rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

Breast Cancer Clinical Trial using capecitabine; paclitaxel albumin-stabilized nanoparticle formulation; neoadjuvant therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer.
capecitabine; paclitaxel albumin-stabilized nanoparticle formulation; neoadjuvant therapy

Colorectal Cancer, or Metastatic Cancer Clinical Trial using floxuridine; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Multi-Institutional Efficacy and Safety Study of Chemotherapy With Selective Internal Radiation Treatment Using Y-90 Microspheres (CHEMO-SIRT) in Patients With Colorectal Cancer Liver Metastasis.
floxuridine; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin

Neuroblastoma Clinical Trial using filgrastim; carboplatin; cisplatin; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; isotretinoin; melphalan; topotecan hydrochloride; vincristine sulfate; vindesine; autologous hematopoietic stem cell transplantation; conventional surgery; peripheral blood stem cell transplantation; iobenguane I 131; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma.
filgrastim; carboplatin; cisplatin; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; isotretinoin; melphalan; topotecan hydrochloride; vincristine sulfate; vindesine; autologous hematopoietic stem cell transplantation; conventional surgery; peripheral blood stem cell transplantation; iobenguane I 131; radiation therapy

Colorectal Cancer Clinical Trial using bevacizumab; capecitabine; fluorouracil; irinotecan hydrochloride; diagnostic laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 80 years.
- Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma.
bevacizumab; capecitabine; fluorouracil; irinotecan hydrochloride; diagnostic laboratory biomarker analysis

Testicular Germ Cell Tumor Clinical Trial using biomarker analysis; computed tomography

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Assessment of the Utility of CT Follow Up in the Long Term Follow Up of Patients With Metastatic Non Seminomatous Germ Cell Tumour (NSGCT).
biomarker analysis; computed tomography

Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystaden Clinical Trial using paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912).
paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Adult Acute Lymphoblastic Leukemia in Remission, Adult Nasal Type Clinical Trial using dasatinib; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
dasatinib; pharmacological study

Lung Cancer Clinical Trial using carboplatin; nitroglycerin; paclitaxel

National Cancer Institute (NCI) - Recruiting 40 years to 80 years.
- A Phase II, Multinational and Multicenter, Randomized, Controlled Study of Paclitaxel and Carboplatin With vs Without Nitroglycerin in Patients With Untreated Advanced Non-small Cell Lung Cancer.
carboplatin; nitroglycerin; paclitaxel

Colorectal Cancer Clinical Trial using medical chart review; survey administration; fecal occult blood test; screening colonoscopy

National Cancer Institute (NCI) - Recruiting 50 years to 74 years.
- Tailored Navigation in CRC Screening.
medical chart review; survey administration; fecal occult blood test; screening colonoscopy

Pain, or Perioperative/Postoperative Complications Clinical Trial using pregabalin; placebo

National Cancer Institute (NCI) - Recruiting 18 years to 70 years.
- Effects of Oral Pregabalin Versus Placebo on Postoperative Pain and Morphine Consumption After Mastectomy.
pregabalin; placebo

Infection, or Leukemia Clinical Trial using alemtuzumab; polymerase chain reaction; flow cytometry; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Consolidation Therapy With Alemtuzumab (MabCampathr) in Patients With Chronic Lymphocytic Leukemia Who Are in Complete or Partial 2nd Remission After Cytoreduction With Fludarabine or Fludarabine Plus Cyclophosphamide or Fludarabine Plus Cyclophosphamide Plus Rituximab or Bendamustine or Bendamustine Plus Rituximab - a Phase I/II Study.
alemtuzumab; polymerase chain reaction; flow cytometry; laboratory biomarker analysis; pharmacological study

Cervical Cancer Clinical Trial using cisplatin; pemetrexed disodium

National Cancer Institute (NCI) - Recruiting N/A or older.
- A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix.
cisplatin; pemetrexed disodium

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using hydroxychloroquine; temozolomide; TdT-mediated dUTP nick end labeling assay; western blotting; electron microscopy; high performance liquid chromatography; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; mass spectrometry; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Hydroxychloroquine in Combination With Temozolomide in Patients With Advanced Solid Tumors.
hydroxychloroquine; temozolomide; TdT-mediated dUTP nick end labeling assay; western blotting; electron microscopy; high performance liquid chromatography; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; mass spectrometry; pharmacological study

Chemotherapeutic Agent Toxicity, Lymphoma, Mucositis, or Neurotox Clinical Trial using glucarpidase; leucovorin calcium; methotrexate; laboratory biomarker analysis; quality-of-life assessment; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients With Primary Central Nervous Lymphoma (PCNSL).
glucarpidase; leucovorin calcium; methotrexate; laboratory biomarker analysis; quality-of-life assessment; radiation therapy

Breast Cancer Clinical Trial using polymorphism analysis; laboratory biomarker analysis; questionnaire administration

National Cancer Institute (NCI) - Recruiting 18 years to 70 years.
- A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Breast Cancer in East Anglia.
polymorphism analysis; laboratory biomarker analysis; questionnaire administration

Healthy, no Evidence of Disease Clinical Trial using polymorphism analysis; laboratory biomarker analysis; questionnaire administration

National Cancer Institute (NCI) - Recruiting 35 years to 69 years.
- A Population Based Control Collection for Genetic Studies in East Anglia.
polymorphism analysis; laboratory biomarker analysis; questionnaire administration

Breast Cancer Clinical Trial using cyclophosphamide; docetaxel; doxorubicin hydrochloride

National Cancer Institute (NCI) - Recruiting 21 years or older.
- A Randomised Phase 2 Study of Neoadjuvant Docetaxel and Cyclophosphamide Compared to Doxorubicin and Cyclophosphamide in Operable Node Negative Breast Cancer With Normal Topoisomerase IIà Expression.
cyclophosphamide; docetaxel; doxorubicin hydrochloride

Kidney Cancer, or Metastatic Cancer Clinical Trial using sunitinib malate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study, Multicenter, Open-label, Evaluating Efficacy of Treatment With Sutentr (Sunitinib) in Patients With Previously Untreated or Recurrent Brain Metastases Originating From Renal Cancer.
sunitinib malate

Breast Cancer Clinical Trial using intensity-modulated radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Trial Testing Dose Escalated Intensity Modulated Radiotherapy for Women Treated by Breast Conservation Surgery and Appropriate Systemic Therapy for Early Breast Cancer.
intensity-modulated radiation therapy

Colorectal Cancer Clinical Trial using FOLFOX regimen; fluorouracil; leucovorin calcium; oxaliplatin; adjuvant therapy; neoadjuvant therapy; quality-of-life assessment; therapeutic surgical procedure

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6.
FOLFOX regimen; fluorouracil; leucovorin calcium; oxaliplatin; adjuvant therapy; neoadjuvant therapy; quality-of-life assessment; therapeutic surgical procedure

Brain and Central Nervous System Tumors Clinical Trial using dasatinib; temozolomide; placebo

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
dasatinib; temozolomide; placebo

Breast Cancer Clinical Trial using anastrozole; exemestane; letrozole; tamoxifen citrate

National Cancer Institute (NCI) - Recruiting N/A to 70 years.
- A Prospective, Randomized, Open-label, Multicenter Study Evaluating the Effects on Cognitive Functions of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer..
anastrozole; exemestane; letrozole; tamoxifen citrate

Leukemia Clinical Trial using flow cytometry; immunologic technique; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 15 years or older.
- A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project.
flow cytometry; immunologic technique; laboratory biomarker analysis

Melanoma (Skin) Clinical Trial using gene expression analysis; mutation analysis; diagnostic laboratory biomarker analysis; immunohistochemistry staining method; sentinel lymph node biopsy

National Cancer Institute (NCI) - Recruiting N/A or older.
- A Retrospective Case-Control Study of Melanoma Patients Who Have Undergone Sentinel Lymph Node Biopsy.
gene expression analysis; mutation analysis; diagnostic laboratory biomarker analysis; immunohistochemistry staining method; sentinel lymph node biopsy

Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial using carboplatin; cyclophosphamide; etoposide phosphate; gene expression analysis; polymorphism analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting N/A to 2 years.
- Pharmacokinetics and Pharmacogenetics of Anticancer Drugs in Infants and Young Children.
carboplatin; cyclophosphamide; etoposide phosphate; gene expression analysis; polymorphism analysis; pharmacological study

Sarcoma Clinical Trial using microarray analysis; molecular diagnostic method; biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting 16 years or older.
- VORTEX-BIOBANK: Prospective Sample Collection for the VORTEX Randomised Radiotherapy Trial in Patients With Extremity Soft Tissue Sarcoma [VORTEX BIOBANK].
microarray analysis; molecular diagnostic method; biologic sample preservation procedure

Distal Urethral Cancer, Metastatic Transitional Cell Cancer of th Clinical Trial using gemcitabine hydrochloride; cisplatin; placebo; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma.
gemcitabine hydrochloride; cisplatin; placebo; bevacizumab; laboratory biomarker analysis

Lung Cancer Clinical Trial using cisplatin; docetaxel; quality-of-life assessment; radiation therapy; stereotactic radiosurgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Study of Doses Escalation on Efficacy on Cyberknife After Docetaxel-Cisplatin Concomitant Radiotherapy for Non Small Cells Lung Cancer Stage III.
cisplatin; docetaxel; quality-of-life assessment; radiation therapy; stereotactic radiosurgery

Cervical Cancer Clinical Trial using cetuximab; cisplatin

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Randomized Assessing Pelvic Irradiation Combined With Cisplatin Alone or Cisplatin Plus Cetuximab in Patients With Carcinoma of the Cervix Stage IB2, II and III.
cetuximab; cisplatin

Pancreatic Cancer Clinical Trial using efavirenz; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Trial to Assess the Efficacy of Efavirenz as Second-line Monotherapy for the Treatment of Advanced Pancreatic Adenocarcinomas..
efavirenz; quality-of-life assessment

Head and Neck Cancer, or Precancerous Condition Clinical Trial using aminolevulinic acid hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors.
aminolevulinic acid hydrochloride

Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystade Clinical Trial using paclitaxel; carboplatin; bevacizumab; veliparib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE I STUDY OF INTRAVENOUS CARBOPLATIN/PACLITAXEL OR INTRAVENOUS AND INTRAPERITONEAL PACLITAXEL/CISPLATIN IN COMBINATION WITH CONTINUOUS OR INTERMITTENT/ CTEP-SUPPLIED AGENT ABT-888 (NSC #737664) AND CTEP-SUPPLIED AGENT BEVACIZUMAB (NSC #704865) IN NEWLY DIAGNOSED PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
paclitaxel; carboplatin; bevacizumab; veliparib; laboratory biomarker analysis

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using bortezomib; carboplatin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE I PHARMACOKINETIC STUDY OF INTRAPERITONEAL CTEP-SUPPLIED AGENT BORTEZOMIB (PS-341, NSC 681239, IND# 58443) AND CARBOPLATIN (NSC# 241240) IN PATIENTS WITH PERSISTENT OR RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER.
bortezomib; carboplatin; pharmacological study

Cognitive/Functional Effects, Fallopian Tube Cancer, Ovarian Canc Clinical Trial using systemic chemotherapy; questionnaire administration; assessment of therapy complications; cognitive assessment; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer.
systemic chemotherapy; questionnaire administration; assessment of therapy complications; cognitive assessment; quality-of-life assessment

Prostate Cancer Clinical Trial using counseling intervention; educational intervention; quality-of-life assessment; therapeutic conventional surgery; iodine I 125; palladium Pd 103

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Surgery and Brachytherapy: A Randomized Evaluation. Randomized Controlled Trial of Brachytherapy Versus Radical Prostatectomy in Good Risk Prostate Cancer: A Feasibility Study.
counseling intervention; educational intervention; quality-of-life assessment; therapeutic conventional surgery; iodine I 125; palladium Pd 103

Breast Cancer Clinical Trial using trastuzumab; lapatinib ditosylate; laboratory biomarker analysis; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study - Biological Phase (EPHOS-B).
trastuzumab; lapatinib ditosylate; laboratory biomarker analysis; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

Colorectal Cancer Clinical Trial using FOLFIRI regimen; fluorouracil; irinotecan hydrochloride; leucovorin calcium; zibotentan; laboratory biomarker analysis; pharmacogenomic studies

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) With or Without the Addition of an Endothelin Receptor Antagonist in Patients With Metastatic Colorectal Cancer After Failure of Oxaliplatin-Containing Chemotherapy.
FOLFIRI regimen; fluorouracil; irinotecan hydrochloride; leucovorin calcium; zibotentan; laboratory biomarker analysis; pharmacogenomic studies

Recurrent Thyroid Cancer, Stage I Follicular Thyroid Cancer, Stag Clinical Trial using cediranib maleate; lenalidomide; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer.
cediranib maleate; lenalidomide; laboratory biomarker analysis

Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Pro Clinical Trial using Akt inhibitor MK2206; bicalutamide; clinical observation

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy.
Akt inhibitor MK2206; bicalutamide; clinical observation

Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Nec Clinical Trial using 18F-fluoromisonidazole; fluorescence angiography; laboratory biomarker analysis; infrared thermography; magnetic resonance imaging; therapeutic conventional surgery; [18F]-ML-10; fludeoxyglucose F 18; rubidium Rb-82

National Cancer Institute (NCI) - Recruiting N/A or older.
- Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation.
18F-fluoromisonidazole; fluorescence angiography; laboratory biomarker analysis; infrared thermography; magnetic resonance imaging; therapeutic conventional surgery; [18F]-ML-10; fludeoxyglucose F 18; rubidium Rb-82

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma.
riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcin Clinical Trial using Akt inhibitor MK2206; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II, 2-stage, 2-arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer.
Akt inhibitor MK2206; laboratory biomarker analysis

Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Clinical Trial using cholecalciferol; genistein; placebo; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Undergoing Prostatectomy.
cholecalciferol; genistein; placebo; laboratory biomarker analysis; pharmacological study

Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Clinical Trial using asparaginase; daunorubicin hydrochloride; mitoxantrone hydrochloride; sorafenib tosylate; cytarabine; etoposide; bortezomib; pharmacological study; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A to 29 years.
- A Phase III Randomized Trial for Patients With de Novo AML Using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD.
asparaginase; daunorubicin hydrochloride; mitoxantrone hydrochloride; sorafenib tosylate; cytarabine; etoposide; bortezomib; pharmacological study; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using vorinostat; stereotactic body radiation therapy; laboratory biomarker analysis; pharmacological study; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma.
vorinostat; stereotactic body radiation therapy; laboratory biomarker analysis; pharmacological study; therapeutic conventional surgery

Breast Cancer Clinical Trial using letrozole; laboratory biomarker analysis; questionnaire administration; breast imaging study; dynamic contrast-enhanced magnetic resonance imaging; neoadjuvant therapy; quality-of-life assessment; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS).
letrozole; laboratory biomarker analysis; questionnaire administration; breast imaging study; dynamic contrast-enhanced magnetic resonance imaging; neoadjuvant therapy; quality-of-life assessment; therapeutic conventional surgery

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using alisertib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma.
alisertib; pharmacological study; laboratory biomarker analysis

Healthy, no Evidence of Disease, or Prostate Cancer Clinical Trial using selenium; placebo; laboratory biomarker analysis; pharmacological study; Se-methyl-seleno-L-cysteine

National Cancer Institute (NCI) - Recruiting 40 years to 80 years.
- Phase I Multiple Dose Study of 12-Week Treatment by Se-Methyl-L-Cysteine(MSC) and L SeMet in Adult Males.
selenium; placebo; laboratory biomarker analysis; pharmacological study; Se-methyl-seleno-L-cysteine

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using dinaciclib; epirubicin hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer.
dinaciclib; epirubicin hydrochloride; laboratory biomarker analysis

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma.
gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using ipilimumab; recombinant interferon alfa-2b; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma.
ipilimumab; recombinant interferon alfa-2b; laboratory biomarker analysis

Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial using tivantinib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 13 Months to 21 years.
- A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND# 112603) in Children With Relapsed or Refractory Solid Tumors.
tivantinib; pharmacological study; laboratory biomarker analysis

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using dinaciclib; Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Dinaciclib (SCH727965) and MK-2206 in Metastatic Pancreatic Cancer With an Expansion Cohort in Advanced Pancreatic Cancer.
dinaciclib; Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcom Clinical Trial using tivantinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma.
tivantinib; laboratory biomarker analysis

Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III S Clinical Trial using cetuximab; intensity-modulated radiation therapy; ipilimumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase Ib Trial of Concurrent Cetuximab (ERBITUXr) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOYr) in Locally Advanced Head and Neck Cancer.
cetuximab; intensity-modulated radiation therapy; ipilimumab; laboratory biomarker analysis

Lung Cancer Clinical Trial using carboplatin; cisplatin; gemcitabine hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC).
carboplatin; cisplatin; gemcitabine hydrochloride

Extrahepatic Bile Duct Cancer, Gallbladder Cancer, or Liver Cance Clinical Trial using cisplatin; fluorouracil; gemcitabine hydrochloride; oxaliplatin

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract.
cisplatin; fluorouracil; gemcitabine hydrochloride; oxaliplatin

Lung Cancer Clinical Trial using erlotinib hydrochloride; sorafenib tosylate; DNA analysis; mutation analysis; polymerase chain reaction; protein analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multicenter, Open-label, Phase II Study of Sorafenib in Combination With Erlotinib in Non-small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens.
erlotinib hydrochloride; sorafenib tosylate; DNA analysis; mutation analysis; polymerase chain reaction; protein analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis

B-cell Childhood Acute Lymphoblastic Leukemia, Peripheral T-cell Clinical Trial using dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase 1 Study of Temsirolimus in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.
dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous S Clinical Trial using doxorubicin hydrochloride; cytarabine; daunorubicin hydrochloride; prednisone; pegaspargase; methotrexate; leucovorin calcium; cyclophosphamide; mercaptopurine; nelarabine; asparaginase; dexamethasone; thioguanine; vincristine sulfate; radiation therapy; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 1 year to 30 years.
- Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma.
doxorubicin hydrochloride; cytarabine; daunorubicin hydrochloride; prednisone; pegaspargase; methotrexate; leucovorin calcium; cyclophosphamide; mercaptopurine; nelarabine; asparaginase; dexamethasone; thioguanine; vincristine sulfate; radiation therapy; laboratory biomarker analysis

Breast Cancer, Cervical Cancer, Endometrial Cancer, or Ovarian Ca Clinical Trial using fluorouracil; pegylated liposomal doxorubicin hydrochloride; hyperthermia treatment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I-II Trial of Mild Whole-Body Hyperthermia Combined With Liposomal Doxorubicin/5-Fluorouracil in Patients With Advanced Malignancy.
fluorouracil; pegylated liposomal doxorubicin hydrochloride; hyperthermia treatment

Brain and Central Nervous System Tumors Clinical Trial using antineoplaston A10; antineoplaston AS2-1

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Primary Malignant Brain Tumors.
antineoplaston A10; antineoplaston AS2-1

Kidney Cancer Clinical Trial using therapeutic allogeneic lymphocytes; cyclophosphamide; cyclosporine; fludarabine phosphate; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- Phase II Trial in Intrafamilial Allogeneic Cell Transplant in Patients With Metastatic Kidney Cancer.
therapeutic allogeneic lymphocytes; cyclophosphamide; cyclosporine; fludarabine phosphate; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

Lymphoma Clinical Trial using bleomycin sulfate; cyclophosphamide; etoposide; mitoxantrone hydrochloride; prednisolone; procarbazine hydrochloride; vinblastine sulfate

National Cancer Institute (NCI) - Recruiting 60 years or older.
- A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ò 60 Years.
bleomycin sulfate; cyclophosphamide; etoposide; mitoxantrone hydrochloride; prednisolone; procarbazine hydrochloride; vinblastine sulfate

Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia Clinical Trial using anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells.
anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

Anemia, Leukemia, or Neutropenia Clinical Trial using fludarabine phosphate; methotrexate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- First Line Therapy With Methotrexate (MTX) and Second Line Therapy With Fludarabine of Patients With T-Cell Large Granular Lymphocyte Leukemia (T-LGL).
fludarabine phosphate; methotrexate

Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovari Clinical Trial using fentanyl citrate; hydromorphone hydrochloride; ropivacaine hydrochloride

National Cancer Institute (NCI) - Recruiting N/A or older.
- Outcomes of Perioperative Epidural Analgesia in Gynecologic Oncology Patients: A Parallel Prospective Cohort and Randomized Clinical Study.
fentanyl citrate; hydromorphone hydrochloride; ropivacaine hydrochloride

Prostate Cancer Clinical Trial using gonadotrophin releasing hormone; cyproterone acetate; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A to 79 years.
- Intermittent Hormone Therapy for Newly Diagnosed Metastatic Prostate Cancer.
gonadotrophin releasing hormone; cyproterone acetate; quality-of-life assessment

Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell L Clinical Trial using entinostat; azacitidine; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer.
entinostat; azacitidine; pharmacological study; laboratory biomarker analysis

Prostate Cancer Clinical Trial using cyproterone acetate; releasing hormone agonist therapy; hypofractionated radiation therapy; intensity-modulated radiation therapy

National Cancer Institute (NCI) - Recruiting N/A or older.
- Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP.
cyproterone acetate; releasing hormone agonist therapy; hypofractionated radiation therapy; intensity-modulated radiation therapy

Lung Cancer Clinical Trial using cisplatin; gemcitabine hydrochloride; adjuvant therapy; conventional surgery; neoadjuvant therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer.
cisplatin; gemcitabine hydrochloride; adjuvant therapy; conventional surgery; neoadjuvant therapy

Prostate Cancer Clinical Trial using goserelin acetate; adjuvant therapy; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase III Randomized Study of Adjuvant Radiotherapy With Versus Without Concurrent Goserelin in Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer.
goserelin acetate; adjuvant therapy; radiation therapy

Chemotherapeutic Agent Toxicity, Sarcoma, or Unspecified Childhoo Clinical Trial using gene expression analysis; polymorphism analysis; management of therapy complications

National Cancer Institute (NCI) - Recruiting N/A to 20 years.
- CYP3A5 Genotype as a Potential Risk Factor for the Development of Ifosamide Nephrotoxicity in Children.
gene expression analysis; polymorphism analysis; management of therapy complications

Breast Cancer Clinical Trial using pegfilgrastim; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride; proteomic profiling; diagnostic laboratory biomarker analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; pharmacological study; surface-enhanced laser desorption/ionization-time of flight mass spectrometry; adjuvant therapy

National Cancer Institute (NCI) - Recruiting 70 years or older.
- Adjuvant Cytotoxic Chemotherapy In Older Women.
pegfilgrastim; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride; proteomic profiling; diagnostic laboratory biomarker analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; pharmacological study; surface-enhanced laser desorption/ionization-time of flight mass spectrometry; adjuvant therapy

Lung Cancer, or Thromboembolism Clinical Trial using dalteparin; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- FRAGMATIC - A Randomised Phase III Clinical Trial Investigating the Effect of FRAGMin Added to Standard Therapy In Patients With Lung Cancer.
dalteparin; quality-of-life assessment

Lung Cancer Clinical Trial using erlotinib hydrochloride; stereotactic body radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Trial of Erlotinib (Tarcevar) in Combination With Stereotactic Body Radiation Therapy (SBRT) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
erlotinib hydrochloride; stereotactic body radiation therapy

Colorectal Cancer Clinical Trial using laboratory biomarker analysis; computed tomography; magnetic resonance imaging; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 50 years or older.
- A Randomised Controlled Trial to Assess the Cost-effectiveness of Intensive Versus no Scheduled Follow-up in Patients Who Have Undergone Resection for Colorectal Cancer With Curative Intent. (FACS - Follow-up After Colorectal Surgery).
laboratory biomarker analysis; computed tomography; magnetic resonance imaging; quality-of-life assessment

Lung Cancer Clinical Trial using cisplatin; etoposide; irinotecan hydrochloride; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years to 75 years.
- Phase II Trial Irinotecan and Cisplatin Induction Chemotherapy Followed by Radiotherapy Concurrently With Etoposide/Cisplatin in Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer.
cisplatin; etoposide; irinotecan hydrochloride; radiation therapy

Lymphoma Clinical Trial using bleomycin sulfate; filgrastim; rituximab; cyclophosphamide; cytarabine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; methotrexate; prednisolone; prednisone; vincristine sulfate; vindesine

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma (IELSG 26).
bleomycin sulfate; filgrastim; rituximab; cyclophosphamide; cytarabine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; methotrexate; prednisolone; prednisone; vincristine sulfate; vindesine

Colorectal Cancer Clinical Trial using polymorphism analysis; laboratory biomarker analysis; questionnaire administration

National Cancer Institute (NCI) - Recruiting 18 years to 69 years.
- A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Colorectal Cancer in East Anglia.
polymorphism analysis; laboratory biomarker analysis; questionnaire administration

Prostate Cancer, or Psychosocial Effects of Cancer and Its Treatm Clinical Trial using questionnaire administration; survey administration; psychosocial assessment and care

National Cancer Institute (NCI) - Recruiting 18 years or older.
- PROSTATE CANCER SYMPTOM MANAGEMENT FOR LOW LITERACY MEN.
questionnaire administration; survey administration; psychosocial assessment and care

Colorectal Cancer, or Primary Peritoneal Cavity Cancer Clinical Trial using fluorouracil; leucovorin calcium; oxaliplatin; hyperthermia treatment

National Cancer Institute (NCI) - Recruiting 18 years to 70 years.
- Phase III Study Evaluating the Use of Systemic Chemotherapy and Chemohyperthemia Intraperitoneal Preoperatively (CHIP) and After Maximum Resection of Peritoneal Carcinomatosis Originating With Colorectal Cancer.
fluorouracil; leucovorin calcium; oxaliplatin; hyperthermia treatment

Breast Cancer, Depression, Long-term Effects of Cancer Treatment, Clinical Trial using educational intervention; informational intervention; internet-based intervention; questionnaire administration; study of socioeconomic and demographic variables; survey administration; psychosocial assessment and care; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A or older.
- Cancer Information Service Research Consortium: Years 2006-2011 Program Narrative and Overview.
educational intervention; informational intervention; internet-based intervention; questionnaire administration; study of socioeconomic and demographic variables; survey administration; psychosocial assessment and care; quality-of-life assessment

Breast Cancer Clinical Trial using quality-of-life assessment; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Multicenter (Phase II) Study of Oncoplastic Surgical Techniques for Breast Conservation in Breast Cancers.
quality-of-life assessment; therapeutic conventional surgery

Breast Cancer Clinical Trial using cyclophosphamide; docetaxel; epirubicin hydrochloride; fluorouracil; neoadjuvant therapy; therapeutic conventional surgery; hypofractionated radiation therapy; image-guided radiation therapy; radiation therapy; stereotactic radiosurgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study - Hypofractionated Cyberknife Radiotherapy Combined With Neoadjuvant Chemotherapy for Breast Tumors.
cyclophosphamide; docetaxel; epirubicin hydrochloride; fluorouracil; neoadjuvant therapy; therapeutic conventional surgery; hypofractionated radiation therapy; image-guided radiation therapy; radiation therapy; stereotactic radiosurgery

Breast Cancer, or Metastatic Cancer Clinical Trial using temozolomide; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer.
temozolomide; radiation therapy

Breast Cancer, or Healthy, no Evidence of Disease Clinical Trial using exercise intervention; counseling intervention; gas chromatography; immunoenzyme technique; immunologic technique; laboratory biomarker analysis; mass spectrometry; physiologic testing; questionnaire administration; survey administration; dual x-ray absorptometry; magnetic resonance imaging; study of high risk factors

National Cancer Institute (NCI) - Recruiting 18 years to 35 years.
- Women In Steady Exercise Research (WISER) Sister.
exercise intervention; counseling intervention; gas chromatography; immunoenzyme technique; immunologic technique; laboratory biomarker analysis; mass spectrometry; physiologic testing; questionnaire administration; survey administration; dual x-ray absorptometry; magnetic resonance imaging; study of high risk factors

Colorectal Cancer Clinical Trial using informational intervention; medical chart review; screening questionnaire administration; study of socioeconomic and demographic variables; barium enema injection; colon imaging study; screening colonoscopy; sigmoidoscopy

National Cancer Institute (NCI) - Recruiting 50 years to 79 years.
- Increasing Colon Cancer Screening in Primary Care Among African Americans.
informational intervention; medical chart review; screening questionnaire administration; study of socioeconomic and demographic variables; barium enema injection; colon imaging study; screening colonoscopy; sigmoidoscopy

Breast Cancer Clinical Trial using microarray analysis; polymerase chain reaction; protein expression analysis; diagnostic laboratory biomarker analysis; fluorescent antibody technique; immunohistochemistry staining method; immunologic technique

National Cancer Institute (NCI) - Recruiting N/A or older.
- Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort.
microarray analysis; polymerase chain reaction; protein expression analysis; diagnostic laboratory biomarker analysis; fluorescent antibody technique; immunohistochemistry staining method; immunologic technique

Leukemia, or Lymphoma Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A to 30 years.
- A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens.
biologic sample preservation procedure

brca1 Mutation Carrier, brca2 Mutation Carrier, or Breast Cancer Clinical Trial using DNA analysis; mutation analysis; polymorphism analysis; laboratory biomarker analysis; evaluation of cancer risk factors

National Cancer Institute (NCI) - Recruiting 18 years to 80 years.
- Genetic Modifiers of BRCA1/BRCA2-Related Breast Cancer Risk in BRCA1/BRCA2 Mutation Carriers - CIMBA 5.
DNA analysis; mutation analysis; polymorphism analysis; laboratory biomarker analysis; evaluation of cancer risk factors

Cancer Clinical Trial using DNA analysis; reverse transcriptase-polymerase chain reaction; biologic sample preservation procedure; flow cytometry; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies.
DNA analysis; reverse transcriptase-polymerase chain reaction; biologic sample preservation procedure; flow cytometry; laboratory biomarker analysis

Sarcoma Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A or older.
- A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens.
biologic sample preservation procedure

Brain and Central Nervous System Tumors Clinical Trial using hydroxyurea; imatinib mesylate

National Cancer Institute (NCI) - Recruiting 18 years to 75 years.
- IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study.
hydroxyurea; imatinib mesylate

Bladder Cancer Clinical Trial using cisplatin; specimen ultra-high-field magnetic resonance imaging; 3-Tesla magnetic resonance imaging; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; functional magnetic resonance imaging; magnetic resonance spectroscopic imaging; neoadjuvant therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Imaging of Bladder Cancer Using Clinical 3 Tesla MRI and EX-VIVO Ultra-High-Field MRI..
cisplatin; specimen ultra-high-field magnetic resonance imaging; 3-Tesla magnetic resonance imaging; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; functional magnetic resonance imaging; magnetic resonance spectroscopic imaging; neoadjuvant therapy

Neuroblastoma Clinical Trial using isotretinoin; DNA analysis; polymerase chain reaction; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting N/A to 18 years.
- Pilot Study to Investigate the Feasibility of 13-cis-retinoic Acid Pharmacokinetic Monitoring in High-risk Neuroblastoma Patients.
isotretinoin; DNA analysis; polymerase chain reaction; laboratory biomarker analysis; pharmacological study

Prostate Cancer Clinical Trial using pharmacological study; questionnaire administration; assessment of therapy complications; high-intensity focused ultrasound ablation; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A or older.
- An Evaluation of Lesion Control Using Focal Ablation With High Intensity Focused Ultrasound in the Treatment of Non-Metastatic Progressive Prostate Cancer.
pharmacological study; questionnaire administration; assessment of therapy complications; high-intensity focused ultrasound ablation; quality-of-life assessment

Recurrent Adult Diffuse Large Cell Lymphoma Clinical Trial using selumetinib; diagnostic laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Single-Arm Phase II Clinical Trial With the Novel MEK Inhibitor AZD-6244 for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
selumetinib; diagnostic laboratory biomarker analysis

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL.
ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Clinical Trial using veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy.
veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using ipilimumab; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma.
ipilimumab; rituximab; laboratory biomarker analysis

Adenomatous Polyp, Colorectal Cancer, or Obesity Clinical Trial using metformin hydrochloride; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 35 years to 80 years.
- A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index.
metformin hydrochloride; pharmacological study; laboratory biomarker analysis

Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Le Clinical Trial using sorafenib tosylate; bone marrow transplantation; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance.
sorafenib tosylate; bone marrow transplantation; laboratory biomarker analysis

Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Sta Clinical Trial using bevacizumab; anti-endoglin monoclonal antibody TRC105; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Study of Bevacizumab Alone or in Combination With TRC 105 for Advanced Renal Cell Cancer.
bevacizumab; anti-endoglin monoclonal antibody TRC105; laboratory biomarker analysis; pharmacological study

BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, or Unspecified Ad Clinical Trial using veliparib; dinaciclib; carboplatin; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1 Trial of ABT-888 and SCH727965 Without or With Carboplatin in Patients With Advanced Solid Tumors.
veliparib; dinaciclib; carboplatin; laboratory biomarker analysis; pharmacological study

Recurrent Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lu Clinical Trial using trametinib; carboplatin; paclitaxel; intensity-modulated radiation therapy; 3-dimensional conformal radiation therapy; image-guided radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-Small Cell Lung Cancer.
trametinib; carboplatin; paclitaxel; intensity-modulated radiation therapy; 3-dimensional conformal radiation therapy; image-guided radiation therapy; pharmacological study; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors.
dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

Precancerous Condition Clinical Trial using naproxen; placebo; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch Repair Deficient Colorectal Cancer.
naproxen; placebo; laboratory biomarker analysis

BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Recurrent Breast Clinical Trial using veliparib; carboplatin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-associated Breast Cancer.
veliparib; carboplatin; laboratory biomarker analysis

Clear Cell Renal Cell Carcinoma, or Stage IV Renal Cell Cancer Clinical Trial using entinostat; aldesleukin; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18; positron emission tomography; computed tomography

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma.
entinostat; aldesleukin; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18; positron emission tomography; computed tomography

Progressive Hairy Cell Leukemia, Initial Treatment, Refractory Ha Clinical Trial using ibrutinib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia.
ibrutinib; laboratory biomarker analysis; pharmacological study

Endometrial Adenocarcinoma, Endometrial Papillary Serous Carcinom Clinical Trial using trametinib; Akt inhibitor GSK2141795; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study With Safety Lead-in to Assess the Antitumor Efficacy of the Mek Inhibitor Trametinib Alone or in Combination With GSK2141795, an Akt Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer.
trametinib; Akt inhibitor GSK2141795; laboratory biomarker analysis

Distal Urethral Cancer, Metastatic Transitional Cell Cancer of th Clinical Trial using eribulin mesylate; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency.
eribulin mesylate; laboratory biomarker analysis; pharmacological study

Recurrent Adult Hodgkin Lymphoma Clinical Trial using temsirolimus; brentuximab vedotin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma.
temsirolimus; brentuximab vedotin; laboratory biomarker analysis

Hepatic Complications, Liver Metastases, or Unspecified Adult Sol Clinical Trial using trametinib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction.
trametinib; pharmacological study; laboratory biomarker analysis

Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, C Clinical Trial using triapine; cisplatin; external beam radiation therapy; brachytherapy; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study of Intravenous 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (3-AP, Triapiner NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and Stage II-IVA Vaginal Cancer.
triapine; cisplatin; external beam radiation therapy; brachytherapy; laboratory biomarker analysis

Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineobla Clinical Trial using temozolomide; irinotecan hydrochloride; bevacizumab

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial.
temozolomide; irinotecan hydrochloride; bevacizumab

Recurrent Small Cell Lung Cancer Clinical Trial using veliparib; temozolomide; placebo; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multi-center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer.
veliparib; temozolomide; placebo; laboratory biomarker analysis

Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage I Follicu Clinical Trial using cabozantinib-s-malate; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy.
cabozantinib-s-malate; laboratory biomarker analysis

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using tivantinib; cetuximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of ARQ 197 (Tivantinib) /Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer.
tivantinib; cetuximab; laboratory biomarker analysis

HIV Infection, or Unspecified Adult Solid Tumor, Protocol Specifi Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Recurrent Thyroid Cancer Clinical Trial using lapatinib ditosylate; dabrafenib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer.
lapatinib ditosylate; dabrafenib; pharmacological study; laboratory biomarker analysis

Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood A Clinical Trial using WEE1 inhibitor MK-1775; radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 37 Months to 21 years.
- A Phase 1 Study of MK-1775 Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas.
WEE1 inhibitor MK-1775; radiation therapy; pharmacological study; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of CTLA-4 Blockade for BRAF Mutant Melanoma.
dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

Recurrent Neuroblastoma Clinical Trial using temozolomide; irinotecan hydrochloride; temsirolimus; monoclonal antibody Ch14.18; sargramostim; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A or older.
- A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408) in Children With Refractory, Relapsed or Progressive Neuroblastoma.
temozolomide; irinotecan hydrochloride; temsirolimus; monoclonal antibody Ch14.18; sargramostim; laboratory biomarker analysis

Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, or Clinical Trial using cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study Comparing Cabozantinib With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma.
cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesop Clinical Trial using radiation therapy; paclitaxel; carboplatin; trastuzumab; therapeutic conventional surgery; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Trial Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of Her2-Overexpressing Esophageal Adenocarcinoma.
radiation therapy; paclitaxel; carboplatin; trastuzumab; therapeutic conventional surgery; laboratory biomarker analysis; quality-of-life assessment

Adult Primary Hepatocellular Carcinoma, Localized Unresectable Ad Clinical Trial using sorafenib tosylate; placebo; doxorubicin hydrochloride; doxorubicin-eluting beads; cisplatin; mitomycin C

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion.
sorafenib tosylate; placebo; doxorubicin hydrochloride; doxorubicin-eluting beads; cisplatin; mitomycin C

Recurrent Melanoma, or Stage IV Melanoma Clinical Trial using NA17.A2 peptide vaccine; recombinant MAGE-3.1 antigen; recombinant interleukin-12; MART-1 antigen; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma.
NA17.A2 peptide vaccine; recombinant MAGE-3.1 antigen; recombinant interleukin-12; MART-1 antigen; laboratory biomarker analysis